Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: A meta-analysis

Gut

Volumn 67, Issue 11, 2018, Pages 2025-2034

  Cacoub, Patrice ^a,b,c,d   Desbois, Anne Claire ^a,b,c,d   Comarmond, Cloe ^a,b,c,d   Saadoun, David ^a,b,c,d  

^a SORBONNE UNIVERSITÉ   (France)

^b Inflammation Immunopathology Biotherapy Department (DHU i2B)   (France)

^c Unit of Dermatology   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

antiviral therapy; extrahepatic manifestations; hepatitis C; meta analysis

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; CARDIOVASCULAR RISK; CHRONIC HEPATITIS C; CLINICAL EVALUATION; CRYOGLOBULINEMIA; CRYOGLOBULINEMIA VASCULITIS; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; EXTRAHEPATIC MANIFESTATION; FATIGUE; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; KIDNEY DISEASE; LIVER DISEASE; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT B CELL LYMPHOPROLIFERATIVE DISEASE; META ANALYSIS; MORTALITY RATE; PATIENT ISOLATION; PRIORITY JOURNAL; REMISSION; SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW; VASCULITIS; COMPLICATION; DRUG EFFECT; HEPACIVIRUS; MORTALITY; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; SURVIVAL RATE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85049151633     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2018-316234     Document Type: Article

References (45)

1. WHO. Global hepatitis C infection report. 2017 http://www. who. int/ hepatitis/ publications/ global-hepatitis-report2017/ en/.
2. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
3. Lavanchy D. The global burden of hepatitis C. Liver International 2009;29:74-81.
4. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTI VIRC Group. Multidepartment Virus C. Arthritis Rheum 1999;42:2204-12.
5. El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011;53:150-7.
6. Lee MH, Yang HI, Lu SN, Sn L, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469-77.
7. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012;26:401-12.
8. Omland LH, Jepsen P, Krarup H, et al. Increased mortality among persons infected with hepatitis C virus. Clin Gastroenterol Hepatol 2011;9:71-8.
9. Uto H, Stuver SO, Hayashi K, et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology 2009;50:393-9.
10. Zignego AL, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol 2007;13:2467-78.
11. Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9:509-16.
12. Hsu YC, Lin JT, Ho HJ, Hj H, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014;59:1293-302.
13. Zignego AL, Ramos-Casals M, Ferri C, et al. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev 2017;16:523-41.
14. Adinolfi LE, Zampino R, Restivo L, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol 2014;20:3410-7.
15. Kawamura Y, Ikeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007;120:1034-41.
16. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
17. Nahon P, Bourcier V, Layese R, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017;152:142-56.
18. Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 2015;64:495-503.
19. Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol 2017;14:122-32.
20. Nuño Solinís R, Arratibel Ugarte P, Rojo A, et al. Value of treating all stages of chronic hepatitis C: a comprehensive review of clinical and economic evidence. Infect Dis Ther 2016;5:491-508.
21. Cacoub P, Comarmond C, Domont F, et al. Cryoglobulinemia vasculitis. Am J Med 2015;128:950-5.
22. Monti G, Pioltelli P, Saccardo F, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 2005;165:101-5.
23. de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium. Clin Gastroenterol Hepatol 2008;6:451-8.
24. Allison RD, Tong X, Moorman AC , et al. Increased incidence of cancer and cancerrelated mortality among persons with chronic hepatitis C infection, 2006-2010. J Hepatol 2015;63:822-8.
25. Visco C, Wang J, Tisi MC, et al. Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. Br J Cancer 2017;117:1685-8.
26. Hosry J, Miranda RN, Samaniego F, et al. Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients. Int J Cancer 2018;142:31110.
27. Torres HA, Shigle TL, Hammoudi N, et al. The oncologic burden of hepatitis C virus infection: a clinical perspective. CA Cancer J Clin 2017;67:411-31.
28. Cacoub P, Gragnani L, Comarmond C, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014;15:8.
29. Younossi Z, Park H, Henry L, et al. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 2016;150:1599-608.
30. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008;49:831-44.
31. Desbois AC , Cacoub P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: a contemporary review. World J Gastroenterol 2017;23:1697-711.
32. Shiffman ML, Gunn NT. Impact of hepatitis C virus therapy on metabolism and public health. Liver Int 2017;37 Suppl 1:13-18.
33. Ramos-Casals M, Zignego AL, Ferri C, et al. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol 2017;66:1282-99.
34. Heimbach JK, Kulik LM, Finn R, et al. Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology 2017;28:29086.
35. European Association for the Study of the Liver. Electronic address: easloffice@ easloffice. eu. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017;66:153-94.
36. Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol 2014;61(1 Suppl):S69-S78.
37. Singh S, Singh PP, Singh AG , et al. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013;108:881-91.
38. Spengler U. Direct antiviral agents (DAAs)-a new age in the treatment of hepatitis C virus infection. Pharmacol Ther 2017;10:30246-2.
39. Jakobsen JC, Nielsen EE, Feinberg J, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;18.
40. Gragnani L, Visentini M, Fognani E, et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology 2016;64:1473-82.
41. Lauletta G, Russi S, Pavone F, et al. Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience. Arthritis Res Ther 2017;19:017-1280.
42. Cacoub P, Vautier M, Desbois AC , et al. Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France. Aliment Pharmacol Ther 2018;47:14382.
43. Nuño-Solinís R, Herrera Molina E, Librada Flores S, et al. [Care costs and activity in the last three months of life of cancer patients who died in the Basque Country (Spain)]. Gac Sanit 2017;31:524-30.
44. Millman AJ, Nelson NP, Vellozzi C. Hepatitis c: review of the epidemiology, clinical care, and continued challenges in the direct acting antiviral era. Curr Epidemiol Rep 2017;4:174-85.
45. Gentile I, Scotto R, Zappulo E, et al. Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opin Investig Drugs 2016;25:557-72.